Ocular Hypertension Epidemiology Forecast Insight

DelveInsight’s ‘Ocular Hypertension–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Ocular Hypertension Disease Understanding

OHT is a condition in which the measured eye pressure (intraocular pressure or IOP) is consistently greater than normal. Elevated intraocular pressure (IOP) is a leading risk factor for developing primary open-angle glaucoma (POAG) and the only modifiable risk factor at present. Patients with elevated IOP and no signs of POAG on standard clinical tests are referred to as having OHT (OHT). Managing this large group of people is time-consuming and costly for patients, clinicians and society—the high prevalence of OHT and its relationship to the potentially blinding disease, POAG.

 

Ocular hypertension is caused by a malfunction of the drainage system for the aqueous humor, the fluid whose function is to bathe and nourish the ocular structures. When it does not flow correctly for different reasons, the balance between the fluid produced inside the eye and the fluid released from it is broken, leading to an increase in intraocular pressure.

Since there are no early signs and symptoms for OHT, the disease often goes unnoticed until it progresses to glaucoma. Ocular hypertension is detected through a comprehensive eye examination in which the value of the intraocular pressure is measured using a test known as tonometry.

Ocular Hypertension Epidemiology

The Ocular Hypertension epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Ocular Hypertension epidemiology segmented as the Prevalent cases of Ocular Hypertension , Gender-specific prevalent case of Ocular Hypertension, Age-specific prevalent cases of Ocular Hypertension and Treated- cases of Ocular Hypertension. The report includes the prevalent scenario of Ocular Hypertension symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Ocular Hypertension Epidemiology

The epidemiology segment also provides the Ocular Hypertension epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total Prevalent population of Ocular Hypertension Associated in 7MM countries was estimated to be 20,817,647 cases in 2020 and expected to increase at a CAGR of 0.64 % for the study period i.e. 2018–2030.
  • As per the estimates, US has the highest prevalent population of Ocular Hypertension with 8,772,815 prevalent cases in 2020.
  • Among the EU5 countries, Germany had the highest prevalent population of Ocular Hypertension. On the other hand, Spain had the lowest number of prevalent cases in 2020.

Scope of the Report

  • Ocular Hypertension report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Ocular Hypertension Epidemiology Report and Model provide an overview of the risk factors and global trends of Ocular Hypertension in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Ocular Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Ocular Hypertension
  • The report provides the segmentation of the Ocular Hypertension epidemiology by Prevalent Cases of Ocular Hypertension in 7MM
  • The report provides the segmentation of the Ocular Hypertension epidemiology by Age-specific Prevalent Cases of Ocular Hypertension in 7MM

Report Highlights

  • 10-year Forecast of Ocular Hypertension epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Ocular Hypertension
  • Prevalent Cases according to segmentation: Type-specific Prevalence of Ocular Hypertension, Gender-specific Prevalence of Ocular Hypertension, Treated Cases of Ocular Hypertension

KOL- Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Ocular Hypertension?
  • What are the key findings of Ocular Hypertension epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Ocular Hypertension across the 7MM during the forecast period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of Ocular Hypertension?
  • What are the currently available treatments for Ocular Hypertension?

Reasons to buy

The Ocular Hypertension Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Ocular Hypertension market
  • Quantify patient populations in the global Ocular Hypertension market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Ocular Hypertension therapeutics in each of the markets covered
  • Understand the magnitude of Ocular Hypertension population by its prevalent cases
  • Understand the magnitude of Ocular Hypertension population by its type and gender-specific cases
  • The Ocular Hypertension Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Ocular Hypertension Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Ocular Hypertension in 2018

3.2. Patient Share (%) Distribution of Ocular Hypertension in 2030

4. Executive Summary of Ocular Hypertension

5. Disease Background and Overview

5.1. Introduction

5.2. Causes

5.3. Physiology and pathogenesis

5.4. Morphology

5.5. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of OHT

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Ocular Hypertension in the United States

6.4.2. Gender-specific Prevalence of Ocular Hypertension in the United States

6.4.3. Age-specific Prevalence of Ocular Hypertension in the United States

6.4.4. Treated cases of Ocular Hypertension in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalent Cases of Ocular Hypertension in Germany

6.5.1.2. Gender-specific Prevalence of Ocular Hypertension in Germany

6.5.1.3. Age-specific Prevalence of Ocular Hypertension in Germany

6.5.1.4. Treated cases of Ocular Hypertension in Germany

6.5.2. France

6.5.2.1. Prevalent Cases of Ocular Hypertension in France

6.5.2.2. Gender-specific Prevalence of Ocular Hypertension in France

6.5.2.3. Age-specific Prevalence of Ocular Hypertension in France

6.5.2.4. Treated Cases of Ocular Hypertension in France

6.5.3. Italy

6.5.3.1. Prevalent Cases of Ocular Hypertension in Italy

6.5.3.2. Gender-specific Prevalence of Ocular Hypertension in Italy

6.5.3.3. Age-specific Prevalence of Ocular Hypertension in Italy

6.5.3.4. Treated Cases of Ocular Hypertension in Italy

6.5.4. Spain

6.5.4.1. Prevalent Cases of Ocular Hypertension in Spain

6.5.4.2. Gender-specific Prevalence of Ocular Hypertension in Spain

6.5.4.3. Age-specific Prevalence of Ocular Hypertension in Spain

6.5.4.4. Treated cases of Ocular Hypertension in Spain

6.5.5. United Kingdom

6.5.5.1. Prevalent Cases of Ocular Hypertension in the United Kingdom

6.5.5.2. Gender-specific Prevalence of Ocular Hypertension in the United Kingdom

6.5.5.3. Age-specific Prevalence of Ocular Hypertension in the United Kingdom

6.5.5.4. Treated Cases of Ocular Hypertension in the United Kingdom

6.6. Japan

6.6.1. Prevalent Cases of Ocular Hypertension in Japan

6.6.2. Gender-specific Prevalence of Ocular Hypertension in Japan

6.6.3. Age-specific Prevalence of Ocular Hypertension in Japan

6.6.4. Treated Cases of Ocular Hypertension in Japan

7. Treatment

7.1. Frequency and follow-up

7.2. Uncertainties regarding best practice for managing ocular hypertension

7.3. Progression to Glaucoma

8. NICE Recommendations and Guidelines

8.1. Case-finding

8.2. Diagnosis

8.3. Standard practice for all assessments

8.4. Reassessment tests

8.5. Treatment

8.6. Stopping treatment for people with OHT or suspected POAG

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Ocular Hypertension, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Prevalent Patient Population of Ocular Hypertension in 7MM in 000’s (2018–2030)

Table 3: Prevalent Cases of Ocular Hypertension in the United States in (2018–2030)

Table 4: Gender-specific Prevalence of Ocular Hypertension in the United States in (2018–2030)

Table 5: Age-specific Prevalence of Ocular Hypertension in the United States in (2018–2030)

Table 6: Treated Cases of Ocular Hypertension in the United States in (2018–2030)

Table 7: Prevalent Cases of Ocular Hypertension in Germany in (2018–2030)

Table 8: Gender-specific Prevalence of Ocular Hypertension in Germany in (2018–2030)

Table 9: Age-specific Prevalence of Ocular Hypertension in Germany in (2018–2030)

Table 10: Diagnosed Cases of Ocular Hypertension in Germany in (2018–2030)

Table 11: Prevalent Cases of Ocular Hypertension in France in (2018–2030)

Table 12: Gender-specific Prevalence of Ocular Hypertension in France in (2018–2030)

Table 13: Age-specific Prevalence of Ocular Hypertension in France (2018–2030)

Table 14: Treated Cases of Ocular Hypertension in France (2018–2030)

Table 15: Prevalent Cases of Ocular Hypertension in Italy in (2018–2030)

Table 16: Gender-specific Prevalence of Ocular Hypertension in Italy in (2018–2030)

Table 17: Age-specific Prevalence of Ocular Hypertension in Italy in (2018–2030)

Table 18: Diagnosed Cases of Ocular Hypertension in Italy in (2018–2030)

Table 19: Prevalent Cases of Ocular Hypertension in Spain in (2018–2030)

Table 20: Gender-specific Prevalence of Ocular Hypertension in Spain in (2018–2030)

Table 21: Age-specific Prevalence of Ocular Hypertension in Spain in (2018–2030)

Table 22: Treated Cases of Ocular Hypertension in Spain in (2018–2030)

Table 23: Prevalent Cases of Ocular Hypertension in the United Kingdom in (2018–2030)

Table 24: Gender-specific Prevalence of Ocular Hypertension in the United Kingdom in (2018–2030)

Table 25: Age-specific Prevalence of Ocular Hypertension in Japan in (2018–2030)

Table 26: Treated Cases of Ocular Hypertension in the United Kingdom in (2018–2030)

Table 27: Prevalent Cases of Ocular Hypertension in Japan in (2018–2030)

Table 28: Gender-specific Prevalence of Ocular Hypertension in Japan in (2018–2030)

Table 29: Age-specific Prevalence of Ocular Hypertension in Japan in (2018–2030)

Table 30: Treated Cases of Ocular Hypertension in Japan in (2018–2030)

List of Figures

Figure 1: Prevalent Patient Population of Ocular Hypertension in 7MM (2018–2030)

Figure 2: Prevalent Cases of Ocular Hypertension in the United States (2018–2030)

Figure 3: Gender-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Figure 4: Age-specific Prevalence of Ocular Hypertension in the United States (2018–2030)

Figure 5: Treated Cases of Ocular Hypertension in the United States (2018–2030)

Figure 6: Prevalent Cases of Ocular Hypertension in Germany (2018–2030)

Figure 7: Gender-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Figure 8: Age-specific Prevalence of Ocular Hypertension in Germany (2018–2030)

Figure 9: Treated Cases of Ocular Hypertension in Germany (2018–2030)

Figure 10: Prevalent Cases of Ocular Hypertension in France (2018–2030)

Figure 11: Gender-specific Prevalence of Ocular Hypertension in France (2018–2030)

Figure 12: Age-specific Prevalence of Ocular Hypertension in France (2018–2030)

Figure 13: Treated Cases of Ocular Hypertension in France (2018–2030)

Figure 14: Prevalent Cases of Ocular Hypertension in Italy (2018–2030)

Figure 15: Gender-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Figure 16: Age-specific Prevalence of Ocular Hypertension in Italy (2018–2030)

Figure 17: Diagnosed Cases of Ocular Hypertension in Italy (2018–2030)

Figure 18: Prevalent Cases of Ocular Hypertension in Spain (2018–2030)

Figure 19: Gender-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Figure 20: Age-specific Prevalence of Ocular Hypertension in Spain (2018–2030)

Figure 21: Treated Cases of Ocular Hypertension in Spain (2018–2030)

Figure 22: Prevalent Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 23: Gender-specific Prevalence of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 24: Age-specific Prevalence of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 25: Treated Cases of Ocular Hypertension in the United Kingdom (2018–2030)

Figure 26: Prevalent Cases of Ocular Hypertension in Japan (2018–2030)

Figure 27: Gender-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Figure 28: Age-specific Prevalence of Ocular Hypertension in Japan (2018–2030)

Figure 29: Treated Cases of Ocular Hypertension in Japan (2018–2030)

Forward to Friend

Need A Quote